Application of beta sodium aescine in preparation of medicine for treating leukemia

A technique for sodium aescin and leukemia is applied in the application field of β-escin sodium in the preparation of medicines for treating leukemia, which can solve the problem that the research on β-escin sodium has not been reported, and achieves the induction of leukemia cell apoptosis. , The dose-effect relationship is obvious, and the anti-tumor activity is strong.

Inactive Publication Date: 2005-11-02
ZHEJIANG UNIV OF TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there is no report on the study of β-escin sodium in

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of beta sodium aescine in preparation of medicine for treating leukemia
  • Application of beta sodium aescine in preparation of medicine for treating leukemia
  • Application of beta sodium aescine in preparation of medicine for treating leukemia

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0021] Example 1: β-Aescin inhibits the proliferation of K562 cells and induces apoptosis

[0022] 1Materials and methods

[0023] 1.1 Main reagents and instruments

[0024] β-Aescinate sodium was purchased from Yantai Luye Pharmaceutical Co., Ltd., batch number 20021006, with a purity of 88.6%. The IMDM culture broth was used to prepare the working solution of the required concentration, and the bacteria were sterilized by positive pressure filtration with a 0.25μm pore filter membrane. save. Annexin V-FITC was purchased from PharMingen, and PI was provided by Sigma. Flow cytometer, Coulter Corporation, Epics-XL type.

[0025] 1.2 Cell culture

[0026] K562 cell line was purchased from Shanghai Institute of Cells at 37,5% CO 2 Under the conditions, with a volume fraction of 10% calf serum, penicillin (1×10 5 U.L -1 ), streptomycin (100μmol.L -1 ) IMDM culture medium is subcultured, and the experimental cells are in the logarithmic growth phase.

[0027] 1.3 Cell proliferation inh...

Example Embodiment

[0055] Example 2: β-Aescinate sodium inhibits HL-60 cell proliferation and induces apoptosis

[0056] 1Materials and methods

[0057] 1.1 Material

[0058] Cells: HL-60 cell line, provided by Shanghai Institute of Cells, Chinese Academy of Sciences.

[0059] Medicine: β-Aescinate sodium was purchased from Yantai Luye Pharmaceutical Co., Ltd., batch number 20021006, with a purity of 88.6%. The working solution of the required concentration was prepared with the culture medium and sterilized by positive pressure filtration with a filter membrane with a 0.25 μm pore size. 4 Store at ℃. Annexin V-FITC was purchased from PharMingen, and PI was provided by Sigma. Flow cytometer, Coulter Corporation, Epics-XL type.

[0060] 1.2 method

[0061] 1.2.1 Cell culture

[0062] HL-60 cells at 37℃, 5% CO 2 Under the conditions, with a volume fraction of 10% calf serum, penicillin (1×10 5 U.L -1 ), streptomycin (100μmol.L -1 ) IMDM culture medium is subcultured, and the experimental cells are in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the application of beta-aescin sodium in preparing medicine for treating leukaemia. Beta-aescin sodium can inhibit K562 and HEALTH-60 cell proliferation and induce leukaemia apoptosis and thus may be used in treating leukaemia. Beta-aescin sodium has powerful extracorporeal antitumor activity, obvious dose-effect relationship and effect strengthened with time. The present invention provides foundation for screening new medicine for leukaemia.

Description

(1) Technical field [0001] The invention relates to the application of beta-escin sodium in the preparation of medicines for treating leukemia. (2) Background technology [0002] Sodium aescin is the total saponin extracted from the dried and mature fruit of the traditional Chinese medicine Suluozi. The main active ingredients are aescin A, B, C, and D. According to the definition of DAC in Germany, aescin A and B are called β- Aescin, C, D aescin is called α-escin. β-Aescinate Sodium has the functions of anti-inflammatory exudation, eliminating swelling, increasing venous tension, improving microcirculation and promoting the recovery of limb functions. This has been confirmed in foreign pharmacological research and clinical practice. It is mainly used in brain Treatment of diseases such as edema, craniocerebral trauma, cerebral infarction, Japanese encephalitis and limb swelling. [0003] Leukemia is a malignant disease of white blood cells in human blood. Its pathologic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704
Inventor 牛泱平
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap